EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitLeitlinieOpen Access · CC BY-NC 4.0

European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection

Felix Sahm iD, Luca Bertero iD, Sebastian Brandner iD, David Capper iD, Roland Goldbrunner, Michael D Jenkinson, Michel Kalamarides, Katrin Lamszus, Nathalie L Albert iD, Maximilian J Mair, Anna S Berghoff, Christian Mawrin und 15 weitere

Neuro-Oncology · 15.05.2025 · 27 (4) · 869-883

DOI: 10.1093/neuonc/noae253 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuro-Oncology, online erschienen am 23.11.2024. Verfasst von Felix Sahm und 26 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuropathology, University Hospital Heidelberg, Heidelberg Gemany and CCU Neuropathology, German Cancer Research Center (DKFZ), German …. Hauptthemen laut MEDLINE: Molecular Targeted Therapy, Meningioma, Meningeal Neoplasms, Biomarkers, Tumor. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 170 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Meningiomas are the most common primary intracranial tumors of adults. For meningiomas that progress or recur despite surgical resection and radiotherapy, additional treatment options are limited due to a lack of proven efficacy. Meningiomas show recurring molecular aberrations, which may serve as predictive markers for systemic pharmacotherapies with targeted drugs or immunotherapy, radiotherapy, or radioligand therapy. Here, we review the evidence for a predictive role of a wide range of molecular alterations and markers including NF2, AKT1, SMO, SMARCE1, PIK3CA, CDKN2A/B, CDK4/6, TERT, TRAF7, BAP1, KLF4, ARID1/2, SUFU, PD-L1, SSTR2A, PR/ER, mTOR, VEGF(R), PDGFR, as well as homologous recombination deficiency, genomic copy number variations, DNA methylation classes, and combined gene expression profiles. In our assessment based on the established ESMO ESCAT (European Society for Medical Oncology Scale for Clinical Actionability of molecular Targets) evidence-level criteria, no molecular target reached ESCAT I (“ready for clinical use”) classification, and only mTOR pathway activation and NF2 alterations reached ESCAT II (“investigational”) classification, respectively. Our evaluations may guide targeted therapy selection in clinical practice and clinical trial efforts and highlight areas for which additional research is warranted.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Targeted TherapyMeningiomaMeningeal NeoplasmsBiomarkers, TumorHumansKruppel-Like Factor 4Europe

Stichwörter der Autor:innen

meningiomapredictive markertargeted therapy

Substanzen

Kruppel-Like Factor 4KLF4 protein, humanBiomarkers, Tumor

Autor:innen und Institutionen

  • Department of Neuropathology, University Hospital Heidelberg, Heidelberg Gemany and CCU Neuropathology, German Cancer Research Center (DKFZ), German Consortium for Translational Cancer Research (DKTK), Heidelberg, Germa…
  • Pathology Unit, Department of Medical Sciences, University of Turin, Turin, Italy.
  • Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology and Division of Neuropathology, University College London Hospitals NHS Foundation Trust, London, UK.
  • German Cancer Consortium (DKTK), partner site Berlin and German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Department of Neuropathology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
  • Department of Neurosurgery, University Hospital Cologne, Cologne, Germany.

ORCID-Profile: Felix Sahm, Luca Bertero, Sebastian Brandner, David Capper, Nathalie L Albert, Leonille Schweizer, Ghazaleh Tabatabai, Emeline Tabouret, Michael Weller, Emilie Le Rhun, Matthias Preusser

Zitieren

APA

Sahm, F., Bertero, L., Brandner, S., Capper, D., Goldbrunner, R., Jenkinson, M. D., Kalamarides, M., Lamszus, K., Albert, N. L., Mair, M. J., Berghoff, A. S., Mawrin, C., Wirsching, H. G., Maas, S. L. N., Raleigh, D. R., Reifenberger, G., Schweizer, L., Suwala, A. K., Tabatabai, G., …, & Preusser, M. (2025). European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection. Neuro-Oncology, 27(4), 869-883. https://doi.org/10.1093/neuonc/noae253

Vancouver

Sahm F, Bertero L, Brandner S, Capper D, Goldbrunner R, Jenkinson MD, et al. European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection. Neuro-Oncology. 2025;27(4):869-883. doi:10.1093/neuonc/noae253

BibTeX
@article{Sahm2025,
  author = {Sahm, Felix and Bertero, Luca and Brandner, Sebastian and Capper, David and Goldbrunner, Roland and Jenkinson, Michael D and Kalamarides, Michel and Lamszus, Katrin and Albert, Nathalie L and Mair, Maximilian J and Berghoff, Anna S and Mawrin, Christian and Wirsching, Hans-Georg and Maas, Sybren L N and Raleigh, David R and Reifenberger, Guido and Schweizer, Leonille and Suwala, Abigail K and Tabatabai, Ghazaleh and Tabouret, Emeline and Short, Susan and Wen, Patrick Y and Weller, Michael and Le Rhun, Emilie and Wesseling, Pieter and van den Bent, Martin and Preusser, Matthias},
  title = {European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection},
  journal = {Neuro-Oncology},
  year = {2025},
  volume = {27},
  number = {4},
  pages = {869--883},
  doi = {10.1093/neuonc/noae253}
}
Kostenlos starten →